{"nctId":"NCT00075725","briefTitle":"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia","startDateStruct":{"date":"2003-12-29","type":"ACTUAL"},"conditions":["Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia","Childhood B Acute Lymphoblastic Leukemia"],"count":3154,"armGroups":[{"label":"Arm I","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Cyclophosphamide","Drug: Cytarabine","Drug: Daunorubicin Hydrochloride","Drug: Dexamethasone","Drug: Doxorubicin Hydrochloride","Drug: Mercaptopurine","Drug: Methotrexate","Drug: Pegaspargase","Radiation: Radiation Therapy","Drug: Thioguanine","Drug: Vincristine Sulfate"]},{"label":"Arm II","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Cyclophosphamide","Drug: Cytarabine","Drug: Daunorubicin Hydrochloride","Drug: Dexamethasone","Drug: Doxorubicin Hydrochloride","Drug: Leucovorin Calcium","Drug: Mercaptopurine","Drug: Methotrexate","Drug: Pegaspargase","Radiation: Radiation Therapy","Drug: Thioguanine","Drug: Vincristine Sulfate"]},{"label":"Arm III","type":"EXPERIMENTAL","interventionNames":["Drug: Cyclophosphamide","Drug: Cytarabine","Drug: Daunorubicin Hydrochloride","Drug: Dexamethasone","Drug: Doxorubicin Hydrochloride","Drug: Mercaptopurine","Drug: Methotrexate","Drug: Pegaspargase","Drug: Prednisone","Radiation: Radiation Therapy","Drug: Thioguanine","Drug: Vincristine Sulfate"]},{"label":"Arm IV","type":"EXPERIMENTAL","interventionNames":["Drug: Cyclophosphamide","Drug: Cytarabine","Drug: Daunorubicin Hydrochloride","Drug: Dexamethasone","Drug: Doxorubicin Hydrochloride","Drug: Leucovorin Calcium","Drug: Mercaptopurine","Drug: Methotrexate","Drug: Pegaspargase","Drug: Prednisone","Radiation: Radiation Therapy","Drug: Thioguanine","Drug: Vincristine Sulfate"]}],"interventions":[{"name":"Cyclophosphamide","otherNames":["(-)-Cyclophosphamide","2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate","Carloxan","Ciclofosfamida","Ciclofosfamide","Cicloxal","Clafen","Claphene","CP monohydrate","CTX","CYCLO-cell","Cycloblastin","Cycloblastine","Cyclophospham","Cyclophosphamid monohydrate","Cyclophosphamide Monohydrate","Cyclophosphamidum","Cyclophosphan","Cyclophosphane","Cyclophosphanum","Cyclostin","Cyclostine","Cytophosphan","Cytophosphane","Cytoxan","Fosfaseron","Genoxal","Genuxal","Ledoxina","Mitoxan","Neosar","Revimmune","Syklofosfamid","WR- 138719"]},{"name":"Cytarabine","otherNames":[".beta.-Cytosine arabinoside","1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone","1-.beta.-D-Arabinofuranosylcytosine","1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone","1-Beta-D-arabinofuranosylcytosine","1.beta.-D-Arabinofuranosylcytosine","2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-","2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-","Alexan","Ara-C","ARA-cell","Arabine","Arabinofuranosylcytosine","Arabinosylcytosine","Aracytidine","Aracytin","Aracytine","Beta-Cytosine Arabinoside","CHX-3311","Cytarabinum","Cytarbel","Cytosar","Cytosine Arabinoside","Cytosine-.beta.-arabinoside","Cytosine-beta-arabinoside","Erpalfa","Starasid","Tarabine PFS","U 19920","U-19920","Udicil","WR-28453"]},{"name":"Daunorubicin Hydrochloride","otherNames":["Cerubidin","Cerubidine","Cloridrato de Daunorubicina","Daunoblastin","Daunoblastina","Daunoblastine","Daunomycin Hydrochloride","Daunomycin, hydrochloride","Daunorubicin.HCl","Daunorubicini Hydrochloridum","FI-6339","Ondena","RP-13057","Rubidomycin Hydrochloride","Rubilem"]},{"name":"Dexamethasone","otherNames":["Aacidexam","Adexone","Aknichthol Dexa","Alba-Dex","Alin","Alin Depot","Alin Oftalmico","Amplidermis","Anemul mono","Auricularum","Auxiloson","Baycadron","Baycuten","Baycuten N","Cortidexason","Cortisumman","Decacort","Decadrol","Decadron","Decadron DP","Decalix","Decameth","Decasone R.p.","Dectancyl","Dekacort","Deltafluorene","Deronil","Desamethasone","Desameton","Dexa-Mamallet","Dexa-Rhinosan","Dexa-Scheroson","Dexa-sine","Dexacortal","Dexacortin","Dexafarma","Dexafluorene","Dexalocal","Dexamecortin","Dexameth","Dexamethasone Intensol","Dexamethasonum","Dexamonozon","Dexapos","Dexinoral","Dexone","Dinormon","Dxevo","Fluorodelta","Fortecortin","Gammacorten","Hexadecadrol","Hexadrol","Lokalison-F","Loverine","Methylfluorprednisolone","Millicorten","Mymethasone","Orgadrone","Spersadex","TaperDex","Visumetazone","ZoDex"]},{"name":"Doxorubicin Hydrochloride","otherNames":["5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)","ADM","Adriacin","Adriamycin","Adriamycin Hydrochloride","Adriamycin PFS","Adriamycin RDF","ADRIAMYCIN, HYDROCHLORIDE","Adriamycine","Adriblastina","Adriblastine","Adrimedac","Chloridrato de Doxorrubicina","DOX","DOXO-CELL","Doxolem","Doxorubicin HCl","Doxorubicin.HCl","Doxorubin","Farmiblastina","FI 106","FI-106","hydroxydaunorubicin","Rubex"]},{"name":"Leucovorin Calcium","otherNames":["Adinepar","Calcifolin","Calcium (6S)-Folinate","Calcium Folinate","Calcium Leucovorin","Calfolex","Calinat","Cehafolin","Citofolin","Citrec","Citrovorum Factor","Cromatonbic Folinico","Dalisol","Disintox","Divical","Ecofol","Emovis","Factor, Citrovorum","Flynoken A","Folaren","Folaxin","FOLI-cell","Foliben","Folidan","Folidar","Folinac","Folinate Calcium","folinic acid","Folinic Acid Calcium Salt Pentahydrate","Folinoral","Folinvit","Foliplus","Folix","Imo","Lederfolat","Lederfolin","Leucosar","leucovorin","Rescufolin","Rescuvolin","Tonofolin","Wellcovorin"]},{"name":"Mercaptopurine","otherNames":["3H-Purine-6-thiol","6 MP","6 Thiohypoxanthine","6 Thiopurine","6-Mercaptopurine","6-Mercaptopurine Monohydrate","6-MP","6-Purinethiol","6-Thiopurine","6-Thioxopurine","6H-Purine-6-thione, 1,7-dihydro- (9CI)","7-Mercapto-1,3,4,6-tetrazaindene","Alti-Mercaptopurine","Azathiopurine","Bw 57-323H","Flocofil","Ismipur","Leukerin","Leupurin","Mercaleukim","Mercaleukin","Mercaptina","Mercaptopurinum","Mercapurin","Mern","NCI-C04886","Puri-Nethol","Purimethol","Purine, 6-mercapto-","Purine-6-thiol (8CI)","Purine-6-thiol, monohydrate","Purinethiol","Purinethol","U-4748","WR-2785"]},{"name":"Methotrexate","otherNames":["Abitrexate","Alpha-Methopterin","Amethopterin","Brimexate","CL 14377","CL-14377","Emtexate","Emthexat","Emthexate","Farmitrexat","Fauldexato","Folex","Folex PFS","Lantarel","Ledertrexate","Lumexon","Maxtrex","Medsatrexate","Metex","Methoblastin","Methotrexate LPF","Methotrexate Methylaminopterin","Methotrexatum","Metotrexato","Metrotex","Mexate","Mexate-AQ","MTX","Novatrex","Rheumatrex","Texate","Tremetex","Trexeron","Trixilem","WR-19039"]},{"name":"Pegaspargase","otherNames":["L-Asparaginase with Polyethylene Glycol","Oncaspar","Oncaspar-IV","PEG-Asparaginase","PEG-L-Asparaginase","PEG-L-Asparaginase (Enzon - Kyowa Hakko)","PEGLA","Polyethylene Glycol L-Asparaginase","Polyethylene Glycol-L-Asparaginase"]},{"name":"Prednisone","otherNames":[".delta.1-Cortisone","1, 2-Dehydrocortisone","Adasone","Cortancyl","Dacortin","DeCortin","Decortisyl","Decorton","Delta 1-Cortisone","Delta-Dome","Deltacortene","Deltacortisone","Deltadehydrocortisone","Deltasone","Deltison","Deltra","Econosone","Lisacort","Meprosona-F","Metacortandracin","Meticorten","Ofisolona","Orasone","Panafcort","Panasol-S","Paracort","Perrigo Prednisone","PRED","Predicor","Predicorten","Prednicen-M","Prednicort","Prednidib","Prednilonga","Predniment","Prednisone Intensol","Prednisonum","Prednitone","Promifen","Rayos","Servisone","SK-Prednisone"]},{"name":"Radiation Therapy","otherNames":["Cancer Radiotherapy","ENERGY_TYPE","Irradiate","Irradiated","Irradiation","Radiation","Radiation Therapy, NOS","Radiotherapeutics","Radiotherapy","RT","Therapy, Radiation"]},{"name":"Thioguanine","otherNames":["2-Amino 6MP","2-Amino-1,7-dihydro-6H-purine-6-thione","2-Amino-6-mercaptopurine","2-Amino-6-purinethiol","2-Aminopurin-6-thiol","2-Aminopurine-6(1H)-thione","2-Aminopurine-6-thiol","2-Aminopurine-6-thiol Hemihydrate","2-Mercapto-6-aminopurine","6-Amino-2-mercaptopurine","6-Mercapto-2-aminopurine","6-Mercaptoguanine","6-TG","6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)","BW 5071","Lanvis","Tabloid","Thioguanine Hemihydrate","Thioguanine Hydrate","Tioguanin","Tioguanine","Wellcome U3B","WR-1141","X 27"]},{"name":"Vincristine Sulfate","otherNames":["Kyocristine","Leurocristine Sulfate","Leurocristine, sulfate","Oncovin","Vincasar","Vincosid","Vincrex","Vincristine, sulfate"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Must be eligible for and enrolled on classification study COG-AALL03B1\n* Newly diagnosed B-precursor acute lymphoblastic leukemia\n\n  * WBC \\> 50,000/mm\\^3 for patients age 1 to 9\n  * Any WBC for patients age 10 to 30 OR patients who have received prior steroid therapy OR patients with testicular disease\n* Whit blood cell (WBC) criteria:\n\n  * Age 1 - 9 years: WBC \\>= 50,000/uL\n  * Age 10 - 30 years: any WBC\n  * Prior steroid therapy: any WBC\n  * Testicular disease: any WBC\n* Patients shall have had no other prior cytotoxic chemotherapy with the exception of steroids and intrathecal cytarabine\n* Patients receiving prior steroid therapy (as described in AALL03B1) are eligible for study; the dose and duration of previous steroid therapy should be carefully documented\n* All patients and/or their parents or legal guardians must sign a written informed consent\n* All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met\n\nExclusion Criteria:\n\n* Patients with Down syndrome are ineligible to enroll onto this study","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Year","maximumAge":"30 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Comparison of the Increase in Cure Rate of High Risk ALL Without Causing More Serious Side Effects Between Interventions","description":"Event Free Probability.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.2","spread":null},{"groupId":"OG001","value":"81.6","spread":null},{"groupId":"OG002","value":"69.1","spread":null},{"groupId":"OG003","value":"91.2","spread":null},{"groupId":"OG004","value":"82.1","spread":null},{"groupId":"OG005","value":"73.5","spread":null},{"groupId":"OG006","value":"80.8","spread":null},{"groupId":"OG007","value":"75.8","spread":null},{"groupId":"OG008","value":"77.0","spread":null},{"groupId":"OG009","value":"61.8","spread":null},{"groupId":"OG010","value":"44.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Correlation of Minimal Residual Disease (MRD) Positive With Overall Survival (OS)","description":"Bone marrow MRD status is defined as positive with \\>= 0.1 detectable leukemia cells, and negative with \\< 0.1 detectable leukemia cells.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.2","spread":null},{"groupId":"OG001","value":"69.9","spread":null},{"groupId":"OG002","value":"65.6","spread":null},{"groupId":"OG003","value":"86.2","spread":null},{"groupId":"OG004","value":"93.8","spread":null},{"groupId":"OG005","value":"63.1","spread":null},{"groupId":"OG006","value":"84.2","spread":null},{"groupId":"OG007","value":"73.6","spread":null},{"groupId":"OG008","value":"74.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Correlation of Minimal Residual Disease (MRD) Negative With Overall Survival (OS).","description":"Bone marrow MRD status is defined as negative with \\< .01 detectable leukemia cells.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.4","spread":null},{"groupId":"OG001","value":"92.9","spread":null},{"groupId":"OG002","value":"87.4","spread":null},{"groupId":"OG003","value":"98.1","spread":null},{"groupId":"OG004","value":"93.3","spread":null},{"groupId":"OG005","value":"90.2","spread":null},{"groupId":"OG006","value":"94.5","spread":null},{"groupId":"OG007","value":"90.5","spread":null},{"groupId":"OG008","value":"91.6","spread":null},{"groupId":"OG009","value":"78.3","spread":null},{"groupId":"OG010","value":"25.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Correlation of Early Marrow Response Status With MRD Positive.","description":"Bone marrow status is defined as: M1: \\< 5% lymphoblasts; M2: 5-25% lymphoblasts; M3: \\> 25% lymphoblasts. Bone marrow MRD status is defined as positive with \\>= 0.1 detectable leukemia cells, and negative with \\< 0.1 detectable leukemia cells.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"43","spread":null},{"groupId":"OG003","value":"14","spread":null},{"groupId":"OG004","value":"16","spread":null},{"groupId":"OG005","value":"95","spread":null},{"groupId":"OG006","value":"17","spread":null},{"groupId":"OG007","value":"98","spread":null},{"groupId":"OG008","value":"39","spread":null},{"groupId":"OG009","value":"3","spread":null},{"groupId":"OG010","value":"3","spread":null},{"groupId":"OG011","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Correlation of Early Marrow Response Status With MRD Negative.","description":"Bone marrow status is defined as: M1: \\< 5% lymphoblasts; M2: 5-25% lymphoblasts; M3: \\> 25% lymphoblasts. Bone marrow MRD status is defined as positive with \\>= 0.1 detectable leukemia cells, and negative with \\< 0.1 detectable leukemia cells.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"182","spread":null},{"groupId":"OG001","value":"72","spread":null},{"groupId":"OG002","value":"198","spread":null},{"groupId":"OG003","value":"188","spread":null},{"groupId":"OG004","value":"195","spread":null},{"groupId":"OG005","value":"471","spread":null},{"groupId":"OG006","value":"190","spread":null},{"groupId":"OG007","value":"479","spread":null},{"groupId":"OG008","value":"208","spread":null},{"groupId":"OG009","value":"25","spread":null},{"groupId":"OG010","value":"3","spread":null},{"groupId":"OG011","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Correlation of Minimal Residual Disease (MRD) Positive With Event Free Survival (EFS)","description":"Bone marrow MRD status is defined as positive with \\>= 0.1 detectable leukemia cells.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.5","spread":null},{"groupId":"OG001","value":"43.3","spread":null},{"groupId":"OG002","value":"35.4","spread":null},{"groupId":"OG003","value":"80","spread":null},{"groupId":"OG004","value":"34.7","spread":null},{"groupId":"OG005","value":"39","spread":null},{"groupId":"OG006","value":"55","spread":null},{"groupId":"OG007","value":"47.8","spread":null},{"groupId":"OG008","value":"49.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Correlation of Minimal Residual Disease (MRD) Negative With Event Free Survival (EFS).","description":"Bone marrow MRD status is defined as negative with \\< 0.1 detectable leukemia cells.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.4","spread":null},{"groupId":"OG001","value":"93.6","spread":null},{"groupId":"OG002","value":"80.5","spread":null},{"groupId":"OG003","value":"93.1","spread":null},{"groupId":"OG004","value":"86.5","spread":null},{"groupId":"OG005","value":"83.4","spread":null},{"groupId":"OG006","value":"84.2","spread":null},{"groupId":"OG007","value":"83.9","spread":null},{"groupId":"OG008","value":"85.3","spread":null},{"groupId":"OG009","value":"74.4","spread":null},{"groupId":"OG010","value":"25","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":16,"n":218},"commonTop":["Neutrophil count decreased","Infections and infestations - Other, specify","Febrile neutropenia","Alanine aminotransferase increased","White blood cell decreased"]}}}